Abstract: Provided herein are liquid pharmaceutical compositions comprising: a fusion protein that comprises a targeting moiety and an immunomodulatory moiety, wherein: i) said targeting moiety specifically binds human epidermal growth factor receptor (hEGFR); and (ii) said immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of human transforming growth factor-beta receptor II (hTGF?RII); a buffer present at a concentration from about 5 mM to about 30 mM; and a tonifying agent present at a concentration from about 4% w/v to about 10% w/v; wherein said liquid pharmaceutical composition has a pH of from about 5.5 to about 7.0. Also provided herein are methods of preparing liquid pharmaceutical composition comprising fusion proteins, and methods of use in treating cancer.

Abstract: A method for making nanomaterials includes introducing into a catalyzed reactor vessel: a carrier gas at a first carrier gas feed rate; at least one carbon-based reactant at a first reactant feed rate; and optionally, at least one additive at a first additive feed rate. The reactor vessel is heated to a first temperature of at least 150° C., so that a portion of the carbon-based reactant within the reactor vessel reacts to form a plurality of nanomaterials. An exhaust gas is removed from the reactor and periodically sampled by exposing a paper web to the gas so that a sample of the nanomaterials from the gas are deposited on a region of the paper web for analysis. Based on this analysis, at least one reaction parameter selected from the group consisting of the first carrier gas feed rate, the first reactant feed rate, and first temperature may be adjusted.